Jacobio Pharmaceuticals Grou Stock price
Is Jacobio Pharmaceuticals Grou a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.
Key metrics
Jacobio Pharmaceuticals Grou Stock Analysis
Analyst Opinions
8 Analysts have issued a Jacobio Pharmaceuticals Grou forecast:
Analyst Opinions
8 Analysts have issued a Jacobio Pharmaceuticals Grou forecast:
Don't miss a Thing! We will send you all news about Jacobio Pharmaceuticals Grou directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Jacobio Pharmaceuticals Group Co., Ltd. is an investment holding company, which engages in the research and development of pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 196 full-time employees. The company went IPO on 2020-12-21. The firm is primarily responsible for the independent discovery and development of innovative tumor therapies. The firm's main drug development projects include JAB-21822 and JAB-3312 clinical stage allosteric SHP2 inhibitors. The firm mainly operates its businesses in China market.
| Head office | Cayman Islands |
| CEO | Dr. Wang |
| Employees | 196 |
| Website | www.jacobiopharma.com |


